The Valley Desk

ArticleJournal of neuromuscular diseasesPublished

Pamrevlumab, a Fully Human Monoclonal Antibody Targeting Connective Tissue Growth Factor, for Non-Ambulatory Patients with Duchenne Muscular Dystrophy

Read the publication ↗ Open access copy ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Children’s Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania. Affiliation source

Publication record

Type
Article
Venue
Journal of neuromuscular diseases
Published
Subject terms
Humans; Muscular Dystrophy, Duchenne; Dystrophin; Antibodies, Monoclonal; Connective Tissue Growth Factor; Antibodies, Monoclonal, Humanized; Monoclonal antibody; Connective tissue growth factor; Duchenne muscular dystrophy; Clinical Trial; Grip Strength; Percent Predicted Forced Vital Capacity
PubMed ID
37248912
PubMed Central ID
PMC10357134
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal